Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (aducanumab) in Subjects with Alzheimer's disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205

Date Added
September 22nd, 2020
PRO Number
Pro00098671
Researcher
Nicholas Milano

List of Studies


Keywords
Alzheimers
Summary

The purpose of this study is to evaluate the long-term safety and effectiveness of the study drug, aducanumab in participants who have previously received aducanumab in the following previous clinical trials: Study 301 [ENGAGE]; Study 302 [EMERGE]; Study 103 [PRIME], and Study 205 [EVOLVE]. The study may last for about 2.5 years consisting of about 33 planned research clinic visits and 8 telephone safety contacts.

Institution
MUSC
Recruitment Contact
Aparna Choudhury
843-792-2845
Choudhur@musc.edu



-- OR --